Cathie Leister

Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

Éric Raymond, Jérôme Alexandre, Sandrine Faivre et al. · Journal of Clinical Oncology · 2004 · 500 citations · Full text

Comparison of the Effects of Zaleplon, Zolpidem, and Triazolam on Memory, Learning, and Psychomotor Performance

Steven Troy, Irwin Lucki, Mary Unruh et al. · Journal of Clinical Psychopharmacology · 2000 · 99 citations

Neuropsychology, Zaleplon 10, Psychopharmacology +20

Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer

Joseph Boni, Cathie Leister, Gregor Bender et al. · Clinical Pharmacology & Therapeutics · 2005 · 87 citations

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects

Richat Abbas, Bruce A. Hug, Cathie Leister et al. · Cancer Chemotherapy and Pharmacology · 2011 · 83 citations

Drug Safety, Pharmacology, Healthy Adult Subjects +5

Effect of Ketoconazole on the Pharmacokinetics of Oral Bosutinib in Healthy Subjects

Richat Abbas, Bruce A. Hug, Cathie Leister et al. · The Journal of Clinical Pharmacology · 2010 · 53 citations

Hematological Malignancy, Oncology, Healthy Subjects +12